In the microscopic theater of human health, a silent drama unfolds—a tale of resilience in the face of adversity, where the protagonists, biofilm, and multidrug-resistant (MDR) pathogens, defy conventional treatments and pose an unprecedented threat. Hospital-acquired infections are on the rise due to the sneaky nature of biofilm, a slimy secretion which serves as a shield for bacteria and has rendered traditional therapies ineffective. Together with biofilm, the alarming growth of multidrug-resistant (MDR) bacteria and fungi in the healthcare environment has created a pressing demand for a novel solution that can break down these imperceptible hurdles to recovery.

In the sphere of infection control, Trifectiv is a ray of hope and innovation. Founded with the goal of improving infection control procedures, Trifectiv is leading the charge in the fight against biofilm and MDR infections. This is more than just a business; it is an answer to a pressing need and a disruptive force in the medical field that is changing the way we understand and manage wound care and infection control. Let us explore Trifectiv’s revolutionary path, where obstacles to infection control become innovations in wound care.

Founded in 2018, Thoclor Labs, a biotech company from Stellenbosch, a university town in the south of South Africa, is a leading innovator in infection control solutions. Through its wound treatment and surgical irrigation product Trifectiv Plus, the company has constantly made break through discoveries on the prophylaxis and management of biofilm and MDR infection and have become a ray of hope in the fight against previously difficult to manage infections.

Trifectiv’s journey started with a dedication to eliminating biofilm, a dangerous and widespread infection problem often associated with implanted devices like prosthetic joint replacements, dental and breast implants, and heart stents. The formation of biofilm is responsible for an astounding 85% of hospital infections, which are frequently unresponsive to traditional therapies. Research from universities confirm that Trifectiv has proven to be successful against living biofilm structures and outperforms standard-of-care therapy currently used for managing biofilm infections, providing a beam of hope in an otherwise hopeless landscape.

Trifectiv’s early-phase deployment entails forging solid alliances with primary care facilities, chemists with in-house primary healthcare clinics, wound care professionals and opinion leaders in orthopedic and other surgical disciplines. Trifectiv is spearheading infection control in the orthopedic and abdominal surgery markets through the provision of CPD-certified training, telemedicine support, and partnerships with leading companies in the industry, including a recent collaboration with a major bone cement supplier.

In-vitro studies demonstrate Trifectiv’s remarkable efficacy in not only eliminating drug-sensitive, but also multidrug-resistant bacteria, as well as biofilm without causing resistance. Trifectiv is far superior to rivals because of its clinical efficacy, two-year stability, simplicity to use and ease of product knowledge transfer, as well as its demonstrated capacity to lower infection process costs. An excellent case example is that of saving the lower limb of a 73-year-old female who sustained a serious lower limb degloving injury. The patient developed biofilm infection in her circumferential lower leg wound which was unresponsive to conventional infection control procedures, with a scheduled lower leg amputation. Trifectiv eliminated the infection, controlled inflammation, and healed her wound. This restored her quality of life and dignity, while significantly lowering treatment costs.

“Trifectiv believes that there is no shortcut to success. Continuous training of medical personnel, intense diligence and aftercare, and the involvement of industry leaders and aligned industry partners (antibiotic bone cement manufacturers) allow us to penetrate the market with credibility and become the go-to wound sepsis prophylaxis and treatment product. We are approaching a critical mass where Trifectiv starts to propel itself as the new generation infection control product,” says Stuart Russell, MD of Trifectiv.

Recognitions and accolades further underscore Trifectiv’s commitment to excellence. In 2023, Dr. Hendrik Roos, Clinical Director received acclaim for the Best Video Presentation titled “The Use of Hypochlorous Acid in an Irradiation Ulcer of the Lower Eyelid – A Case Study.” This notable achievement featured in the Journal of Cancer Science and Treatment (Volume 5, Supplement 1, Page 06). Trifectiv secured the Best Lecture title at the CPD course for medical practitioners held in Johannesburg, South Africa, in July 2022, further solidifying its position as a leader in the field of infection control.

Trifectiv consistently educates medical professionals, develops innovative solutions like hydrogel applications, and establishes significant and strategic partnerships. Trifectiv strives to be the standard product for wound sepsis, with an emphasis on establishing trust in new markets. Trifectiv is more than simply a business—it is a glowing ember of promise for people with chronic wounds. The Trifectiv story exemplifies creativity, kindness, and a never-ending search for improved infection control solutions.